LogicBio Therapeutics

Biotech

AstraZeneca pays 666% premium to buy genomic medicine biotech

Working through its Alexion rare disease unit, the Big Pharma has struck a deal to snap up struggling LogicBio to secure technology and expertise.

Nick Paul Taylor Oct 3, 2022 9:00am

sun rise sun morning sun clouds sky

LogicBio's sun and shares rise after FDA releases clinical hold

May 9, 2022 11:00am

FDA Building

FDA puts LogicBio genome editing therapy trial on hold

Feb 2, 2022 8:10am

CRISPR-Cas9

Intellia, LogicBio fuel hope for in vivo gene editing: report

Oct 25, 2021 10:37am

3D medical background with DNA strand

Next-gen gene therapies for rare diseases forge ahead

Dec 14, 2020 5:28am

FDA

LogicBio rocked by FDA clinical hold on genome editing trial

Feb 11, 2020 8:30am